Logo Logo

Publications by Im, Young-Hyuck

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Tripathy, Debu; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Harbeck, Nadia; Hurvitz, Sara A.; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; Laurentiis, Michelino de; Im, Young-Hyuck; Kümmel, Sherko; El-Saghir, Nagi; Liu, Mei-Ching; Carlson, Gary; Hughes, Gareth; Diaz-Padilla, Ivan; Germa, Caroline; Hirawat, Samit; Lu, Yen-Shen (2018): Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. In: Lancet Oncology, Vol. 19, No. 7: pp. 904-915

Ponde, Noam; Bradbury, Ian; Lambertini, Matteo; Ewer, Michael; Campbell, Christine; Ameels, Helene; Zardavas, Dimitrios; Di Cosimo, Serena; Baselga, Jose; Huober, Jens; Izquierdo, Miguel; Fumagalli, Debora; Bozovic-Spasojevic, Ivana; Maetens, Marion; Harbeck, Nadia; Pusztai, Lajos; Berghorn, Michael; Im, Young-Hyuck; Ruiz Borrego, Manuel; Chen, Dar-Ren; Rodeheffer, Richard; Piccart, Martine; Suter, Thomas; Azambuja, Evandro de (2018): Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). In: Breast Cancer Research and Treatment, Vol. 168, No. 3: pp. 631-638

Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine (2016): Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. In: Lancet Oncology, Vol. 17, No. 3: pp. 357-366

This list was generated on Sat Jan 25 10:12:30 2020 CET.